1.Efficacy and safety of upadacitinib through 140 weeks in Chinese adult and adolescent patients with moderate-to-severe atopic dermatitis: Post hoc analysis of the phase 3 Measure Up 1 and AD Up clinical trials.

Li ZHANG ; Jinhua XU ; Chaoying GU ; Min ZHENG ; Meng PAN ; Linfeng LI ; Michael LANE ; Andrew PLATT ; Shereen HAMMAD ; Qichen FAN ; Xinghua GAO

Chinese Medical Journal 2025;138(13):1633-1634